Yamanouchi Pharmaceutical Company Ltd.

Jun Sekino

Hidemi Shimizu

Kiyoshi Okazaki

Masuo Murakami

Shigemi Kawahara

Hiroitsu Kawata

Hiroitsu Kawada

Hiroshi Maeda

Tadayoshi Ohmura

Toshimitsu Konno

Go Ohtani

Mitsugu Kobayashi

A lyophilized pharmaceutical composition comprised of a neocarzinostatin derivative having the formula (SMA)-(NCS)-(SMA), is made by a method including dissolving the neocarzinostatin derivative and stabilizing agent comprising at least one saccharide selected from the group consisting of monosaccharides, disaccharides and dextran in an aqueous buffer solution having a pH ranging from about 7.5 to about 9.5, the stabilizing agent being present in an amount by weight (titer) which is at least equal to that of the neocarzinostatin derivative, to provide a solution; adjusting the pH of the solution to provide a pH-adjusted solution having a pH of about 8.0.+-.0.5; sterilizing the pH-adjusted solution by filtration to provide a sterilized solution; and lyophilizing the sterilized solution.

Lyophilized pharmaceutical composition of neocarzinostatin derivative

There is disclosed a dry, stabilized oral pharmaceutical formulation containing a prostaglandin E group prepared from a lyophilized composition comprising a prostaglandin E group and at least a member selected from the group consisting of a thiol compound, dextrin, dextran, a lower alkyl cellulose, and a water-soluble salt of deoxycholic acid.

Stabilized oral prostaglandin formulation and the process for the

There is provided a process of preparing a prostaglandin E group-containing formulation by adding to a prostaglandin E group at least one additive selected from the group consisting of thiol compound, a water-soluble high molecular weight compound, and a water-soluble salt of deoxycholic acid and then subjecting the mixture to lyophilization.

Process of preparing stable prostaglandin E group-containing formulation

A dried and stabilized prostaglandin composition containing a prostaglandin E group compound with calcium lactate and/or amylopectin, and a stabilized pharmaceutical preparation for practical administration prepared from the said composition.

Stabilized prostaglandin composition and the process for the preparation

There is provided a process of preparing a prostaglandin E group-containing formulation by adding to a prostaglandin E group at least one additive selected from the group consisting of a thiol compound, a water soluble high molecular weight compound and a water-soluble salt of deoxycholic acid and then subjecting the mixture to lyophilization.

Growing community of inventors

Kashiwa, Japan

Jun Sekino